Core Viewpoint - The company Gan Cao Doctor, an online TCM diagnosis platform, has submitted its listing application to the Hong Kong Stock Exchange, with a valuation of 1.6 billion yuan in its latest financing round, benefiting from AI-assisted TCM diagnosis and the "Internet + TCM" trend [1] Group 1: Company Overview - Gan Cao Doctor is positioned as the largest online TCM comprehensive service provider in China, holding a 4.9% market share [1] - The company reported revenues of 600 million yuan, 690 million yuan, and 550 million yuan for the first three quarters of 2023, 2024, and 2025 respectively [1] - The net profit is expected to reach 10 million yuan in 2024, but the company anticipates a loss in the first three quarters of 2025 [1] Group 2: Operational Challenges - The company acknowledges that its operating performance is directly affected by sales costs, with fluctuations in procurement prices, supply chain disruptions, and seasonal variations in TCM materials potentially impacting unit costs [1] - There are concerns regarding the quality of registered physicians on the platform, as many do not have detailed qualifications, and some claim to specialize in a wide range of conditions without sufficient verification [2] - The platform's regulatory measures and compliance are questioned, with reports of potential kickbacks for physicians, which contradicts national regulations on medical practices [3]

Core Viewpoint - The company Gan Zhicao is preparing for an IPO, having established itself as a leader in China's online traditional Chinese medicine (TCM) sector, but faces challenges with high growth and low profitability [1][5]. Group 1: Company Overview - Gan Zhicao was founded in 2015, inspired by a moment when a co-founder had to write a prescription on a napkin, leading to the idea of integrating TCM with the internet [2]. - The company holds a 4.9% market share in the online TCM comprehensive service market and a 16.7% share in the online TCM diagnosis service segment, significantly outpacing its competitors [2][4]. - The business model leverages digital tools to streamline the entire process from diagnosis to medication and daily health maintenance, serving both patients and small TCM clinics [3]. Group 2: Financial Performance - Revenue is projected to grow from 603 million yuan in 2023 to 690 million yuan in 2024, with 555 million yuan achieved in the first nine months of 2025 [4]. - Despite revenue growth, the company reported a net loss of 123.5 million yuan in the first nine months of 2025, primarily due to increased sales and distribution expenses [6][7]. - The gross profit margin for online TCM diagnosis services is between 22% and 24%, while offline services have a lower margin of 6.7% to 13.4% [6]. Group 3: Market Context - The online TCM comprehensive service market in China has expanded dramatically from 2.7 billion yuan in 2019 to an estimated 13 billion yuan in 2024 [5]. - The company's revenue structure is diversifying, with the share of online TCM diagnosis services decreasing from 85.3% to 70.1%, while SaaS and consumer health products are gaining ground [6]. Group 4: Capital and Governance - Gan Zhicao has seen a significant increase in valuation, rising from under 7 million yuan in early 2023 to over 1.6 billion yuan, a 240-fold increase [8][9]. - The company has engaged in multiple capital operations, including share transfers and investments from various institutions, raising concerns about governance and related party transactions [9][10]. - The company has not yet secured professional medical liability insurance for its online TCM services, which poses potential risks [7].

Company Overview - Gan Zhicao has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities International and Shenwan Hongyuan Hong Kong acting as joint sponsors [1] - The company is a digital-driven online comprehensive service provider in traditional Chinese medicine (TCM), covering online TCM diagnosis, TCM medical institution services, and TCM health products [1] - Gan Zhicao holds a leading position in the market, with a 4.9% market share among the top five online TCM service providers in China, and ranks first in the online TCM diagnosis service market with a 16.7% market share [1] Core Products and Services - The core products include the online diagnosis platform "Gan Cao Doctor," a SaaS and supply chain system "Gan Cao Cloud Manager" designed for TCM medical institutions, and the AI-assisted intelligent diagnosis program "Xuanqi Wendu," developed in collaboration with Zhejiang Chinese Medical University [1] - The company operates a smart shared pharmacy network consisting of 7 self-operated, 7 joint venture, and 52 outsourced pharmacies responsible for the preparation, processing, distribution, and delivery of traditional Chinese medicine [1] - Gan Zhicao has launched the "Gan Cao Life | Gan Zhi Yi" brand, which sells TCM health products [1] Industry Insights - The Chinese TCM industry is experiencing continuous growth, with the market size expected to reach 22,615 billion RMB by 2029 [2]

Company Overview - The company, Hangzhou Gan Zhi Cao Technology Co., Ltd., is a leading online TCM (Traditional Chinese Medicine) comprehensive service provider in China, focusing on online TCM diagnosis and treatment services, TCM medical institution services, and TCM health products [3][4]. - Established in 2015, the company is one of the earliest online TCM service providers in China, holding a market share of 4.9% in the online TCM comprehensive service market, ranking first among its peers [3][4]. Business Model - The company has developed an online diagnosis platform, Gan Cao Doctor, enabling TCM practitioners to provide medical services, and a SaaS and supply chain service system, Gan Cao Cloud Manager, designed for TCM medical institutions [4]. - It has established a smart shared pharmacy network consisting of seven self-operated regional pharmacies, seven joint venture pharmacies, and 52 outsourced pharmacies across China, facilitating the preparation, processing, dispensing, and delivery of TCM [4][5]. Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 is approximately RMB 603 million, RMB 690 million, and RMB 554 million, respectively [6]. - The profit and total comprehensive income for the same periods are RMB 1.875 million, RMB 10.156 million, and a loss of RMB 1.235 million [7]. - The gross profit margin for these periods is 22.8%, 23.4%, and 27% [8]. Industry Overview - The TCM industry in China is projected to grow from RMB 1,079.4 billion in 2019 to RMB 1,448.6 billion in 2024, with a compound annual growth rate (CAGR) of 6.1%, and is expected to reach RMB 2,261.5 billion by 2029, with a future five-year CAGR of 9.3% [11]. - The online TCM service market is anticipated to expand significantly, from RMB 2.7 billion in 2019 to RMB 13 billion in 2024, reflecting a CAGR of 36.5% [11][13].

Company Overview - The company, Hangzhou Gan Zhi Cao Technology Co., Ltd., is a leading online traditional Chinese medicine (TCM) service provider in China, focusing on online TCM diagnosis and treatment services, TCM medical institution services, and TCM health products [3][4] - Established in 2015, the company is one of the earliest online TCM service providers in China, holding a 4.9% market share, making it the largest player in the online TCM comprehensive service market [3][4] - The company has developed its own online diagnosis platform, Gan Cao Doctor, and a SaaS and supply chain service system, Gan Cao Cloud Manager, to enhance service delivery [4][5] Market Position - According to a report by Frost & Sullivan, the company ranks first in the online TCM diagnosis service market with a 16.7% market share as of 2024 [3] - The overall market for online TCM services is expected to grow significantly, with the online comprehensive TCM service market projected to expand from RMB 2.7 billion in 2019 to RMB 13 billion by 2024, reflecting a compound annual growth rate (CAGR) of 36.5% [10][12] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 is approximately RMB 603 million, RMB 690 million, and RMB 554 million, respectively [5][6] - The profit and total comprehensive income for the same periods are RMB 1.875 million, RMB 10.156 million, and a loss of RMB 1.235 million, respectively [6] - The gross profit margin for the same periods is 22.8%, 23.4%, and 27% [7] Industry Overview - The TCM industry in China is projected to grow from RMB 1,079.4 billion in 2019 to RMB 1,448.6 billion by 2024, with a CAGR of 6.1% [10] - The TCM diagnosis service segment is expected to reach approximately RMB 1,001.6 billion by 2024, growing at a CAGR of 10.1% [12] - The overall TCM market is transitioning from a drug-centric model to a more integrated healthcare and wellness development paradigm, supported by favorable policies and technological integration [12]